Suppr超能文献

医用大麻使用者的在线调查:患者层面数据的定性分析。

Online survey of medicinal cannabis users: Qualitative analysis of patient-level data.

作者信息

Garcia-Romeu Albert, Elmore Joshua, Mayhugh Rhiannon E, Schlienz Nicolas J, Martin Erin L, Strickland Justin C, Bonn-Miller Marcel, Jackson Heather, Vandrey Ryan

机构信息

Johns Hopkins University School of Medicine, Baltimore, MD, United States.

University of Colorado Boulder, Boulder, CO, United States.

出版信息

Front Pharmacol. 2022 Sep 6;13:965535. doi: 10.3389/fphar.2022.965535. eCollection 2022.

Abstract

To characterize perceived benefits and challenges experienced by medicinal cannabis users. An anonymous online survey collected demographics, health information, and open-ended responses from medicinal cannabis users regarding perceptions, motivations, and experience of treatment. Qualitative open-ended responses were thematically analyzed. Respondents ( = 808) were predominantly White (79%), female (63%), with a mean (SD) age of 38 (20). Two hundred eighty-four (35%) respondents provided data on a dependent family member (e.g., child; 22% of total sample). Most used cannabidiol (CBD)-dominant products (58%), primarily for neurological disorders (38%) or pain (25%). Primary motivations for medicinal cannabis use were based on beliefs that traditional treatments were ineffective and/or had intolerable side effects (51%), positive scientific or media portrayals of the safety/efficacy of cannabis as a therapeutic (29%), or preference for "natural" treatments over pharmaceuticals (21%). A majority of respondents (77%) attributed positive effects to the medicinal use of cannabis/cannabinoids. These included physical symptom improvements such as reduced pain (28%), improved sleep (18%), and seizure reduction (18%), and mental health improvements including reduced anxiety (22%) and improved mood (11%). Additionally, respondents reported reduced use of other medications (e.g., opioids) (12%), and improved quality of life (14%). Problems associated with use were cited by 41% of respondents, and included unwanted side effects (16%), lack of information or medical support (16%), prohibitive costs (12%), and legal concerns (10%). Most participants reported benefits from cannabis use for a variety of conditions where traditional treatments were ineffective or unacceptable. Concerns regarding cannabis side effects, legality, lack of information, and cost were raised. Data indicate greater research and education on the safety and efficacy of medicinal cannabis/cannabinoid use is warranted.

摘要

描述药用大麻使用者所感受到的益处和挑战。一项匿名在线调查收集了药用大麻使用者的人口统计学信息、健康信息以及关于认知、动机和治疗体验的开放式回答。对定性的开放式回答进行了主题分析。受访者(n = 808)主要为白人(79%),女性(63%),平均(标准差)年龄为38岁(20岁)。284名(35%)受访者提供了关于受抚养家庭成员(如子女;占总样本的22%)的数据。大多数人使用以大麻二酚(CBD)为主的产品(58%),主要用于治疗神经系统疾病(38%)或疼痛(25%)。使用药用大麻的主要动机基于以下信念:传统治疗无效和/或有无法忍受的副作用(51%)、科学或媒体对大麻作为治疗药物的安全性/有效性的正面描述(29%),或相较于药物更倾向于“天然”治疗(21%)。大多数受访者(77%)将积极效果归因于大麻/大麻素的药用。这些包括身体症状的改善,如疼痛减轻(28%)、睡眠改善(18%)和癫痫发作减少(18%),以及心理健康的改善,包括焦虑减轻(22%)和情绪改善(11%)。此外,受访者报告其他药物(如阿片类药物)的使用减少(12%),生活质量提高(14%)。41%的受访者提到了与使用相关的问题,包括不良副作用(16%)、缺乏信息或医疗支持(16%)、费用过高(12%)和法律问题(10%)。大多数参与者报告称,在传统治疗无效或不可接受的各种情况下,使用大麻都有益处。人们对大麻的副作用、合法性、信息缺乏和成本表示担忧。数据表明,有必要对药用大麻/大麻素使用的安全性和有效性进行更多的研究和教育。

相似文献

1
Online survey of medicinal cannabis users: Qualitative analysis of patient-level data.
Front Pharmacol. 2022 Sep 6;13:965535. doi: 10.3389/fphar.2022.965535. eCollection 2022.
4
Use and Reported Helpfulness of Cannabinoids Among Primary Care Patients in Vermont.
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720946954. doi: 10.1177/2150132720946954.
5
Pharmacology of Medical Cannabis.
Adv Exp Med Biol. 2019;1162:151-165. doi: 10.1007/978-3-030-21737-2_8.
6
Homegrown perceptions about the medical use and potential abuse of CBD and THC.
Addict Behav. 2021 Apr;115:106799. doi: 10.1016/j.addbeh.2020.106799. Epub 2020 Dec 24.
8
A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health.
Cannabis Cannabinoid Res. 2021 Dec;6(6):548-558. doi: 10.1089/can.2019.0096. Epub 2020 Jun 8.
9
Mapping cannabis potency in medical and recreational programs in the United States.
PLoS One. 2020 Mar 26;15(3):e0230167. doi: 10.1371/journal.pone.0230167. eCollection 2020.
10
Characterizing Cannabis Use and Perceived Benefit in a Tertiary Headache Center Patient Sample.
Neurol Clin Pract. 2024 Apr;14(2):e200285. doi: 10.1212/CPJ.0000000000200285. Epub 2024 Mar 6.

引用本文的文献

2
Detecting and understanding potential stigma among medical cannabis users in Germany.
BMC Public Health. 2025 Mar 5;25(1):874. doi: 10.1186/s12889-025-22084-w.
3
An Individual's Lived Experiences of Taking Cannabis-Based Medicinal Products (CBMPs) to Treat Anxiety.
Int J Environ Res Public Health. 2023 Sep 18;20(18):6776. doi: 10.3390/ijerph20186776.
4
Oral CBD-rich hemp extract modulates sterile inflammation in female and male rats.
Front Physiol. 2023 May 18;14:1112906. doi: 10.3389/fphys.2023.1112906. eCollection 2023.

本文引用的文献

1
Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial.
Front Psychiatry. 2021 Sep 9;12:729800. doi: 10.3389/fpsyt.2021.729800. eCollection 2021.
2
Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy.
Epilepsy Behav. 2021 Sep;122:108205. doi: 10.1016/j.yebeh.2021.108205. Epub 2021 Jul 27.
3
The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder.
Cannabis Cannabinoid Res. 2022 Apr;7(2):214-223. doi: 10.1089/can.2020.0056. Epub 2020 Dec 9.
4
A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health.
Cannabis Cannabinoid Res. 2021 Dec;6(6):548-558. doi: 10.1089/can.2019.0096. Epub 2020 Jun 8.
5
Clinical uses of cannabis and cannabinoids in the United States.
J Neurol Sci. 2020 Apr 15;411:116717. doi: 10.1016/j.jns.2020.116717. Epub 2020 Jan 30.
6
Benefits and harms of medical cannabis: a scoping review of systematic reviews.
Syst Rev. 2019 Dec 10;8(1):320. doi: 10.1186/s13643-019-1243-x.
7
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
Lancet Psychiatry. 2019 Dec;6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28.
8
Public health implications of legalising the production and sale of cannabis for medicinal and recreational use.
Lancet. 2019 Oct 26;394(10208):1580-1590. doi: 10.1016/S0140-6736(19)31789-1. Epub 2019 Oct 23.
9
Priority Considerations for Medicinal Cannabis-Related Research.
Cannabis Cannabinoid Res. 2019 Sep 23;4(3):139-157. doi: 10.1089/can.2019.0045. eCollection 2019.
10
Use of Cannabis to Relieve Pain and Promote Sleep by Customers at an Adult Use Dispensary.
J Psychoactive Drugs. 2019 Nov-Dec;51(5):400-404. doi: 10.1080/02791072.2019.1626953. Epub 2019 Jul 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验